Perspective Therapeutics reported promising Phase 1/2a trial results for lapemelanotide, a targeted alpha therapy for advanced melanoma. At the 3.0 mCi dose, 75% of patients achieved disease control, including durable stabilization and partial responses lasting up to 40 weeks. The treatment showed no dose-limiting toxicities or serious adverse events in 20 heavily pretreated patients. These findings support further development of lapemelanotide as a potential option for melanoma patients with limited alternatives.
Perspective Therapeutics' lapemelanotide trial results provide context for readers interested in health-sector developments. Among 150 priced Health-sector US stocks tradable on Pluang, 76 rose and 72 fell today. Notable movers include BKD at USD 9.00 with a 1-day change of -16.74%, NTRA at USD 307.70 with a 1-day change of -15.41%, and HALO at USD 106.61 with a 1-day change of -13.30%, as of Nov 06, 2026 23:12 WIB.
Ipsen has disclosed its monthly update on the total number of shares and voting rights as of October 31, 2026. The company reported 83,814,526 shares composing the share capital, with a gross total of 132,059,377 voting rights and a net total of 130,...
Ipsen Pharma has disclosed the total number of shares and voting rights composing its capital as of October 31, 2026. The company reported 83,814,526 shares and a gross total of 132,059,377 voting rights, with a net total of 130,677,690 after excludi...
At its 2026 International User Summit, Chery unveiled its Globalization 3.0 strategy, moving beyond export-driven growth to emphasize deep localization, sustainable development, and community engagement. The company is expanding local R&D, manufactur...
Sodexo disclosed its monthly update on share capital and voting rights as of October 31, 2026. The company has 147,454,887 shares with actual voting rights totaling 216,485,145, reflecting shares with single and double voting rights. This update is p...
Sodexo announced its monthly update on the total number of shares and voting rights as of October 31, 2026. The company has 147,454,887 shares composing its capital, with 216,485,145 exercisable voting rights and 218,335,896 theoretical voting rights...
